<DOC>
	<DOC>NCT00185159</DOC>
	<brief_summary>This is a study in diabetic patients with at least one additional cardiovascular risk factor and normoalbuminuria prior to randomization.</brief_summary>
	<brief_title>Olmesartan Medoxomil in Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<criteria>Diabetes mellitus type 2, defined as fasting blood glucose of greater than or equal to 126 mg/dL; Presence of at least one of the following cardiovascular risk factors: 1. total cholesterol greater than 200 mg/dL or statin treatment, 2. High density lipoprotein (HDL) less than 40 mg/dL, 3. triglycerides greater than 150 mg/dL and less than 400 mg/dL, 4. blood pressure greater than or equal to 130/80 mmHg, 5. Body mass index (BMI) greater than 28 kg/m2, 6. waist circumference greater than 102 cm for men and greater than 88 cm for women, 7. smoking of more than 5 cigarettes a day; Normoalbuminuria at screening Severe uncontrolled hyperlipidemia; Documented renal and/or renalvascular disease; Myocardial infarction, stroke or myocardial revascularization within the last 6 months; History of alcohol and/or drug abuse; Allergic reaction, lack of response or contraindication to angiotensin receptor blockers (ARBs); Current treatment with an ARB or angiotensin converting enzyme (ACE) inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Microalbuminuria</keyword>
</DOC>